This is a single-arm study of daratumumab in metastatic non-small cell lung cancer (NSCLC)
patients with an STK11/LKB1 mutation. Patients will have received previous standard of care
treatment including chemotherapy, immunotherapy and targeted therapy. Patients will be
treated with the standard subcutaneous dosing of daratumumab (weekly for 8 administrations,
then every 2 weeks for 8 administrations then every 4 weeks until progression). All follow-up
visits and imaging will be performed as per standard of care. This is a signal finding study
and an overall response rate ≥20% is considered clinically meaningful.